Doximity director Timothy Cabral sells $1.15 million in stock

SAN FRANCISCO—Timothy S. Cabral, a director at Doximity , Inc. (NYSE:DOCS), has recently sold shares of the company amounting to approximately $1.15 million, according to a recent SEC filing. The transactions took place on February 3, 2025, and were part of a pre-established trading plan adopted on February 15, 2024. The sale comes as Doximity, currently valued at $10.84 billion, trades near its 52-week high of $61.75, having delivered an impressive 126% return over the past six months.

Cabral sold a total of 20,000 shares of Doximity’s Class A Common Stock. The shares were sold at weighted-average prices ranging from $56.8312 to $58.4033 per share. Following these transactions, Cabral retains ownership of 6,360 shares of the company. According to InvestingPro analysis, Doximity maintains exceptional financial health with a perfect Piotroski Score of 9 and industry-leading gross profit margins of nearly 90%.

The sales were conducted automatically under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for selling stocks, helping them avoid potential accusations of insider trading. Cabral’s transactions were executed as part of this plan, ensuring compliance with SEC regulations. For deeper insights into Doximity’s valuation and 18 additional exclusive ProTips, subscribers can access the comprehensive Pro Research Report on InvestingPro.

In other recent news, Doximity Inc has been under the financial microscope with several investment firms adjusting their outlooks. Mizuho (NYSE:MFG) Securities initiated coverage on Doximity with a Neutral rating, emphasizing the company’s recent growth resurgence in fiscal year 2025. However, the firm also advised caution due to the company’s ongoing quarterly volatility. Similarly, JPMorgan maintained a Neutral rating on Doximity but raised the price target to $48, acknowledging Doximity’s solid financial fundamentals and strong financial profile.

Goldman Sachs also initiated coverage on Doximity, setting a Neutral rating and a 12-month price target of $58. The firm expects a steady performance from Doximity resulting in a compound annual growth rate of 9-10% in revenue from the fiscal year 2025 to the fiscal year 2028. Truist Securities increased Doximity’s price target to $49, maintaining a Hold rating on the stock. This adjustment was made following the release of Doximity’s financial results for the second quarter of fiscal year 2025.

Lastly, Morgan Stanley (NYSE:MS) upgraded Doximity’s stock from Underweight to Equalweight, raising the price target to $53. Despite this upgrade, the firm warned of a stretched valuation and raised questions about the potential for Doximity to outperform its fourth-quarter estimates and the growth trajectory for fiscal year 2026. These recent developments indicate a cautious yet optimistic approach by these firms towards Doximity.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.